Tasly Pharma of Tianjin has in-licensed the China rights to an Alzheimer’s drug in clinical development at ProteoTech, Inc. of Seattle. The two companies will co-develop the novel small molecule, Exebryl-1®, for the treatment of mild-to-moderate Alzheimer's disease, working for approval in both the US and China. In 2008, Tasly announced it was beginning Phase I tests of the drug, but no results have ever been released. More details....

Stock Symbol: (SHEX: 600535)